Skip to content
Screener

Kiniksa Pharmaceuticals International, plc KNSA Total Liabilities

Total Liabilities at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$3.42M-97.2%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$136.19M-14.7%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$177.4M+6.1%
Cytokinetics logo
CytokineticsCYTK
$2.1B+31.6%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$82.4M-19.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.64B+44.4%

Other financials

Income statement

See full
Revenue$243.6M+55.4%
Gross profit$220.0M+59.2%
Operating income$27.2M+34.9%
Net income$25.4M+42.6%
EPS (diluted)$0.30+30.4%

Balance sheet

See full
Cash & equivalents$175.7M-8.5%
Total debt$8.9M-8.9%
Total equity$654.1M+32.1%
Total assets$896.1M+35.5%

Cash flow

See full
Operating cash flow$47.2M+68.0%
CapEx$663.0K+302%
Free cash flow$46.5M+66.6%

Valuation

See full
Market cap$5.97B+146%
Enterprise value$5.8B+159%
P/E74×-432×
P/S7.1×+2.5×

Profitability

See full
Gross margin89.8%+3.9pp
Operating margin11.9%+11.1pp
Net margin9.6%+8.7pp
FCF margin21.7%+8.8pp

Returns & leverage

See full
Return on equity14%+13.0pp
Debt / equity0×0.0×
Current ratio3.9×+0.3×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087545
Line itemJune 30, 2026December 31, 2025
Non-current deferred revenue31,81131,811
Non-current operating lease liabilities4,8856,510
Other long-term liabilities34,01818,522
Total liabilities241,961196,027
Commitments and contingencies (Note 13)
Shareholders’ equity:
Class A ordinary shares, nominal value of $0.000273235 per share; 48,244,934 shares and 45,659,424 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively1212
Class B ordinary shares, nominal value of $0.000273235 per share; 895,158 shares and 1,795,158 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively11

Item 1. Financial Statements (unaudited)

FAQ

What is Kiniksa Pharmaceuticals International, plc's total liabilities?
Kiniksa Pharmaceuticals International, plc (KNSA) reported total liabilities of $241.96M in Q2 2026.
How has Kiniksa Pharmaceuticals International, plc's total liabilities changed year-over-year?
Kiniksa Pharmaceuticals International, plc's total liabilities increased by 45.6% year-over-year, from $166.14M to $241.96M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's total liabilities?
Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's total liabilities has grown at a 39.2% compound annual growth rate (CAGR), from $37.53M to $196.03M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Kiniksa Pharmaceuticals International, plc's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude